CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 41 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05161494
NCT05161494N/ACompleted

Identification of Gait Disorders in Children, Adolescents and Young Adults With Rare Genetic Diseases

Universiteit Antwerpen·observational·Posted Dec 17, 2021·Updated May 7, 2026

In Brief

An observational study for Tuberous Sclerosis and STXBP1 Encephalopathy With Epilepsy. Completed, enrolled 41 participants across 1 site.

Detailed Summary

The aim of this pilot study is to explore whether the knowledge and experience gained during the T-GaiD project (Treatment of Gait Disorders in Dravet Syndrome - NCT03857451) can be transferred to other populations with similar problems, i.e. motor and gait problems as a result of a genetic disorder characterized by epilepsy and developmental delay. In this pilot study, 40 people with Tuberous Sclerosis Complex and 30 people with STXBP1 will be recruited via the Antwerp University Hospital and invited for a gait analysis in the M²OCEAN movement lab. The aim of the pilot study is to evaluate the feasibility of the 3D gait analysis protocol and to determine the sensitivity of the primary (summative measure of the severity of gait abnormalities) and the secondary (spatio-temporal and kinematic gait parameters) outcome measures.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesBelgium

Timeline

N/ACompletedFinished
20222023202420252026
First PostedDec 17, 2021
Enrollment StartJan 25, 2022
Primary CompletionJul 1, 2025
Study CompletionJan 30, 2026
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 4.5 years ago